GLP-1 drugs have exploded from niche diabetes treatments to mainstream weight-loss weapons, now used by 11% of U.S. adults—up from just 3% in 2024—but a new side effect and a courtroom showdown are forcing a reality check. A large study of nearly 40,000 patients found that users of Ozempic, Wegovy, and Mounjaro face a small but statistically significant increase in hair loss, though the absolute risk remains low and the shedding is typically reversible. Meanwhile, Novo...